All data are based on the daily closing price as of November 18, 2026
h
Hanmi Pharm. Co.
128940.KO
329.40 USD
-6.41
-1.91%
Overview
Last close
329.40 usd
Market cap
4.18B usd
52 week high
431.89 usd
52 week low
192.05 usd
Target price
478.04 usd
Valuation
P/E
41.046
Forward P/E
N/A
Price/Sales
3.6452
Price/Book Value
4.0394
Enterprise Value
4.27B usd
EV/Revenue
3.4306
EV/EBITDA
14.1882
Key financials
Revenue TTM
1.17B usd
Gross Profit TTM
661.36M usd
EBITDA TTM
230.73M usd
Earnings per Share
8.17 usd
Dividend
1.5 usd
Total assets
1.51B usd
Net debt
128.62M usd
About
Hanmi Pharm. Co., Ltd., a biopharmaceutical company, engages in the manufacture and sale of pharmaceutical products in South Korea, China, Japan, the United States, and internationally. It focuses on research areas with high unmet medical needs, including obesity, metabolism, oncology, and rare diseases. The company's products include Gugutams, a urological combination therapy combining two active ingredients: tamsulosin, a treatment for Obstructive Prostatic Growth (OPG), and tadalafil, a treatment for erectile dysfunction (ED). The company has a research collaboration with MEDIC Life Sciences Inc. to identify cancer biomarkers. The company was founded in 1973 and is based in Hwaseong-si, South Korea.